-

Shareholder Alert: Robbins LLP Announces It Is Investigating Sorrento Therapeutics, Inc. (SRNE) for Misleading Shareholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that it is investigating Sorrento Therapeutics, Inc. (NASDAQ: SRNE) for alleged violations of the Securities Exchange Act of 1934 and whether the Company's officers and directors breached their fiduciary duties to shareholders. Sorrento is a clinical stage biopharma company that develops therapies for cancer, autoimmune, inflammatory, and neurodegenerative diseases.

If you suffered a loss as a result of Sorrento's misconduct, click here.

Sorrento Therapeutics, Inc. (SRNE) Accused of Misleading Investors

On May 15, 2020, Sorrento announced that it had discovered an antibody that had "demonstrated 100% inhibition of SARS-CoV-2 virus infection" and stated on national television "[Sorrento] want[s] to emphasize there is a cure." Following these auspicious statements, Sorrento's stock price soared to as high as $10.00 per share, representing a 281.7% increase from its May, 14, 2020 closing price. However, on May 20, 2020, Hindenburg Research issued a report calling Sorrento's claims "sensational," "nonsense," and "too good to be true" after speaking with Mount Sinai, the company Sorrento was collaborating with, which cautioned that "nothing in medicine is 100%." Finally, on May 22, 2020, BioSpace published an article revealing that in an interview on May 21, 2020, Sorrento's officers "insist[ed] that they did not say it was a cure" but rather that it could potentially be a cure. On this news, Sorrento's stock price fell to $4.93 per share, representing a 49.4% decline from its class period high of $10 per share.

Contact us to learn more:
Leo Kandinov
(800) 350-6003
lkandinov@robbinsllp.com
Shareholder Information Form

Want to be notified if a class action against Sorrento settles? Want to receive free alerts about companies engaged in wrongdoing? Sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

Industry:

Robbins LLP

NASDAQ:SRNE
Release Versions
English
$Cashtags
$SRNE
Hashtags
#ClassAction
#Finance
#Investment
#Investor
#Lawsuit
#Securities
#Shareholder
#Shareholderrights
#StockAlert
#StockMarketData
#StockNews
#StockTrading
#Stocks
#Trader
#shareholderrightslawfirm

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

CPNG Class Action Alert: Robbins LLP Reminds Investors with Losses in Coupang, Inc. to Contact the Firm for Information About Leading the Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Coupang, Inc. (NYSE: CPNG) securities between April 6, 2025 and December 16, 2025. Coupang describes itself as one of the fastest-growing technology and commerce companies in the world, providing retail, restaurant delivery, video streaming, and fintech services to customers around the world under brands that include Coupang, Coupang Eats, Cou...

Vistagen Therapeutics, Inc. Stockholders with Large Losses in VTGN Should Contact Robbins LLP for Information About Leading the Vistagen Therapeutics, Inc. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a class action was filed on behalf of all investors who purchased or otherwise acquired Vistagen Therapeutics, Inc. (NASDAQ: VTGN) common stock between April 1, 2024 and December 16, 2025. Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. For more information, submit a form, email attorney Aaron Dumas...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Beyond Meat, Inc. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Beyond Meat, Inc. (NASDAQ: BYND) securities between February 27, 2025 and November 11, 2025. Beyond Meat operates in the food industry, developing, manufacturing, marketing, and selling plant-based meat products under the "Beyond" brand name in the U.S. and internationally. For more information, submit a form, email attorney Aaron Dumas, Jr.,...
Back to Newsroom